Mainstream

ANI Pharmaceuticals beats top-line and bottom-line estimates; raises FY25 outlook

ANI Pharmaceuticals beats top-line and bottom-line estimates; raises FY25 outlook

Post ContentanipRead More

You might also be interested in reading Bitcoin bull run ‘still too early’ to call as demand lags exiting capital: Analyst.

August 8, 2025
In Mainstream